The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment (original) (raw)
Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, Kraszewski A (1978) Comparative effects of oestrogen and a progestagen on bone loss in postmenopausal women. Clin Sci Mol Med 54:193–195 PubMedCAS Google Scholar
Lindsay R (1987) Prevention of osteoporosis. Clin Orthop Rel Res 222:44–59 Google Scholar
Christiansen CK, Christensen MS, McNair P, Hagen C, Stocklund K, Transbol I (1980) Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273–279 PubMedCAS Google Scholar
Copp DH, Cameron EC, Cheney BA, Davidson AGF, Henze HK (1962) Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70: 638–649 PubMedCAS Google Scholar
Reginster J-Y (1991) Effect of calcitonin on bone mass and fracture rates. Am J Med 91 (suppl): 5B19S-5B22S Google Scholar
Austin LA, Heath H (1981) Calcitonin: physiology and pathophysiology. N Engl J Med 304:269–278 ArticlePubMedCAS Google Scholar
Mazzuoli GF, Passeri M, Gennari M, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effect of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8 PubMedCAS Google Scholar
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 23:295–303 Article Google Scholar
Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment. Am J Med 89:1–6 ArticlePubMedCAS Google Scholar
Reginster JY, Albert A, Lecart MP, Lambelin P, Denis D, Deroisy R, Fontaine MA, Franchimont P (1987) One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1481–1483
Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 199:447–479 Google Scholar
Ljunghall S, Gärdsell P, Johnell O, Larsson K, Lindh E, Obrant K, Sernbo I (1991) Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 49:17–19 PubMedCAS Google Scholar
Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. J Clin Invest 82:1268–1274 PubMedCAS Google Scholar
Haas HG, Liebrich BM, Schaffner W (1990) Calcitonin and osteoporosis—a critical reappraisal of the literature 1980–1989. Klin Wochenschr 68:359–371 ArticlePubMedCAS Google Scholar
Farley JR, Chestnut CH III, Baylink DJ (1981) Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin. Clin Chem 27:2002–2007 PubMedCAS Google Scholar
Bessey OA, Lowry OH, Brock MJ (1946) Method for rapid determination of alkaline phosphatase with 5 cubic millimeters of serum. J Biol Chem 164:321–329 CAS Google Scholar
Podenphant J, Larsen NE, Christiansen C (1984) An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 142:145–148 ArticlePubMedCAS Google Scholar
Woessner JF (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440–447 ArticlePubMedCAS Google Scholar
Black D, Duncan A, Robins SP (1989) Quantitative analysis of the pyrdinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197–203 Article Google Scholar
Seibel MJ, Duncan A, Robins SP (1989) Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J Rheumatol 16:964–970 PubMedCAS Google Scholar
Robins SP (1983) Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. J Biochem 215:167–173 CAS Google Scholar
Greenwood FC, Hunter W, Glover J (1963) Preparation of I-131 labelled human growth hormone of high specific radioactivity. Biochemistry 89:114–123 CAS Google Scholar
Gundry CR, Miller CW, Ramos E, Moscona A, Stein JA, Mazess RB, Sartoris DJ, Resnick D (1990) Dual-energy radiographic absorptiometry of the lumbar spine: clinical experience with two different systems. Radiology 174:539–541 PubMedCAS Google Scholar
Mazess R, Collick B, Trempe J, Barden H, Hanson J (1989) Performance evaluation of a dual-energy X-ray bone densitometer. Calcif Tissue Int 44:228–232 PubMedCAS Google Scholar
Pouilles J-M, Tremollieres F, Todorovsky N, Ribot C (1991) Precision and sensitivity of dual-energy x-ray absorptiometry in spinal osteoporosis. J Bone Miner Res 6:997–1002 ArticlePubMedCAS Google Scholar
Wahner HW, Dunn WL, Brown ML, Riggs BL (1988) Comparison of dual-energy X-ray absorptiometry and dual photon absorptiometry for bone mineral measurements of the lumbar spine. Mayo Clin Proc 63:1075–1084 PubMedCAS Google Scholar
Gennari C, Montagnani P, Nardi P, Zacchei F, Bigazzi C, Cepollaro C (1987) Long-term effect of cyclic or continuous calcitonin treatment on bone mass in established postmenopausal osteoporosis. Osteoporosis II 2:919–921 Google Scholar
Gennari C, Agnusdei D, Cepollaro C, Zacchei F, Palmieri R (1987) Effect of intermittent or continuous long-term calcitonin nasal spray treatment on bone mass in established postmenopausal osteoporosis. Osteoporosis II 3:1323–1329 Google Scholar
Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R (1992) An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 50:381–383 ArticlePubMedCAS Google Scholar
Mazzuoli GF, Tabolli S, Bigi F, Valtorta C, Minisola S, Diacinti D, Scarnecchia L, Bianchi G, Piolini M, Dell'Acqua S (1990) Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int 47:209–214 PubMedCAS Google Scholar
Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A (1992) Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 15:225–232 ArticlePubMedCAS Google Scholar
Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2338 ArticlePubMedCAS Google Scholar
Woodhouse NJY, Mohamedally SM, Saed-Nejad F, Martin TJ (1977) Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. Br Med J 2:927–929 ArticlePubMedCAS Google Scholar
Reginster JY, Mautalen C, Gennari C (1987) Are antibodies against salmon calcitonin able to inhibit the biological efficacy of the drug? In: Osteoporosis 1987. Osteopress Aps, Copenhagen, Denmark, pp 916–918 Google Scholar
Levy F, Muff R, Dotti-Siegrist S, Dambacher MA, Fischer JA (1988) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab 67:541–545 ArticlePubMedCAS Google Scholar
Reginster JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JL, Collette J, Franchimont P (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83–86 PubMedCAS Google Scholar